Allogene Therapeutics (ALLO) Non-Current Assets (2018 - 2026)
Allogene Therapeutics (ALLO) posted Non-Current Assets of $122.7 million for Q1 2026, down 22.44% sequentially from $158.2 million in Q4 2025, and down 43.32% YoY from $216.4 million in Q1 2025.
Allogene Therapeutics (ALLO) Non-Current Assets (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $122.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 43.32% year-over-year to $122.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $647.8 million (down 30.8% YoY) and the FY2025 annual result came in at $158.2 million, down 35.53% from the prior year.
- Non-Current Assets declined to $122.7 million in Q1 2026 per ALLO's latest filing, from $158.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $508.3 million in Q1 2022 and troughed at $122.7 million in Q1 2026.
- A 5-year average of $253.4 million and a median of $240.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets sank 49.48% in 2022, then soared 33.53% in 2024.
- Over 5 years, Non-Current Assets stood at $292.8 million in 2022, then sank by 37.24% to $183.7 million in 2023, then surged by 33.53% to $245.3 million in 2024, then slumped by 35.53% to $158.2 million in 2025, then retreated by 22.44% to $122.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $122.7 million, $158.2 million, and $179.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 210.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210.09 Mn |
| Mar 31, 2026 | 122.67 Mn |
| Dec 31, 2025 | 158.16 Mn |
| Sep 30, 2025 | 179.05 Mn |
| Jun 30, 2025 | 187.94 Mn |
| Mar 31, 2025 | 216.41 Mn |
| Dec 31, 2024 | 245.32 Mn |
| Sep 30, 2024 | 284.71 Mn |
| Jun 30, 2024 | 189.76 Mn |
| Mar 31, 2024 | 190.99 Mn |
| Dec 31, 2023 | 183.72 Mn |
| Sep 30, 2023 | 239.96 Mn |
| Jun 30, 2023 | 270.91 Mn |
| Mar 31, 2023 | 268.66 Mn |
| Dec 31, 2022 | 292.76 Mn |
| Sep 30, 2022 | 325.42 Mn |
| Jun 30, 2022 | 442.59 Mn |
| Mar 31, 2022 | 508.35 Mn |
| Dec 31, 2021 | 579.51 Mn |
| Sep 30, 2021 | 576.39 Mn |